Cyclosporin, azathioprine, prednisone and anti-thymocytic globulin led to a decrease in insulin requirements and enhanced endogenous B-cell function in patients with recent onset of T1D, but the magnitude and duration of benefits were limited and concern over short- and long-term toxicity limited their use [38–43]. The gene discussed is INS; the disease is type 1 diabetes mellitus.